Zdrowie i gospodarka · 16/09/1994

National Institutes of Health to Grant Co-Exclusive License for Second Generation Monoclonal Antibodies Targeting TAG-72

The National Institutes of Health is considering granting co-exclusive licenses to Centocor, Inc. and Miles, Inc. for the use of second generation monoclonal antibodies with high binding affinity and specificity to TAG-72, a tumor-associated glycoprotein, for the treatment of human carcinomas.